Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Share:
Related ILMN
Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook
7 Biggest Price Target Changes For Monday

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

DateFirmActionFromTo
Aug 2017Canaccord GenuityUpgradesHoldBuy
Jul 2017Morgan StanleyMaintainsUnderweight
Mar 2017Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!